Britain’s healthcare cost agency on Tuesday recommended against including Johnson & Johnson’s nasal spray for depression, Spravato, in the country’s healthcare network, citing uncertainties over its clinical and cost effectiveness.
UK healthcare cost agency rejects J&J’s nasal spray for depression
